• Police seek suspects in deadly birthday party shooting
  • Lawmakers launch inquires into U.S. boat strike
  • Nov. 29, 2025, 10:07 PM EST / Updated Nov. 30, 2025,…
  • Mark Kelly says troops ‘can tell’ what orders…

Be that!

contact@bethat.ne.com

 

Be That ! Menu   ≡ ╳
  • Home
  • Travel
  • Culture
  • Lifestyle
  • Sport
  • Contact Us
  • Politics Politics
☰

Be that!

Nov. 15, 2025, 5:15 AM ESTBy Richie Duchon and Nigel ChiwayaA former soccer boss gets a pelting, plus a costly name change and tough-to-swallow tariffs. Test your knowledge of the week in news, and take last week’s quiz here.Richie DuchonRichie Duchon is an NBC News digital editor in the Los Angeles bureau. Nigel ChiwayaNigel Chiwaya is the Senior Editor, Data Viz for NBC News Digital.

admin - Latest News - November 15, 2025
admin
13 views 9 secs 0 Comments




A former soccer boss gets a pelting, plus a costly name change and tough-to-swallow tariffs.



Source link

TAGS:
PREVIOUS
Transgender Air Force members sue federal government
NEXT
Nov. 15, 2025, 5:00 AM ESTBy Alexandra MarquezDemocrats were knocked back on their heels in 2024 by the party’s erosion of support among young men. They were gratified to see improvement with that group in key elections earlier this month.In between, the party has been on a mission to stop its erosion among young voters, launching research efforts, piloting different styles of communication and elevating new voices. And it has already come to one important conclusion, according to interviews in October with a range of people on the left working on the issue: The solution to Democrats’ struggle to appeal to young men won’t come from one national figure who will instantly, magically draw them in.“If not Trump, then who? And the question for the Democratic Party that I think is one of the challenges we have right now is, we don’t have a great answer for that,” Amanda Litman, the founder and executive director of Run for Something, a group that recruits young Democratic candidates for downballot races, told NBC News. “I don’t think Chuck Schumer and Hakeem Jeffries have the answer to that,” she added, referring to the Senate and House minority leaders respectively.But while Democrats may not have one leading figure they can rely on to recruit young male voters, one overarching belief is that they do have popular policies that — if communicated well and in the right spaces — could put the party on a path to victory with young voters.“I don’t think that there is a lack of popularity with Democratic policies. It’s a lack of the ability to appropriately communicate those policies in a way that actually breaks through and resonates with these voters, right?” Danielle Butterfield, the executive director of Priorities USA, told NBC News. “We know that we are always going to be the party that has a more favorable, popular stance on health care and health care costs. The question is, do voters know that, and are we talking about it in places where they’re actually spending time?”The power of the ‘manosphere’In the year since the presidential election, Democrats have aimed to learn why their messaging to young men failed in 2024 and how to fix it.Some, like former Democratic Rep. Colin Allred, who was a collegiate and professional football player in the NFL before running for office, say it’s because Democrats alienated young men with their messaging.“If you listen to many Democratic speeches over the last few years, and you kind of listen to the recitation of policies, if you’re a young man listening into that, you might think that none of those were directed towards you. And I think that was a mistake,” Allred, who is running for Senate again in Texas next year after losing to GOP Sen. Ted Cruz last year, told NBC News.“What I’ve seen is that if somebody agrees with you on policy, but thinks that you don’t understand them, their culture, what they’re going through and where they come from, then they’re still not going to want to support you,” he added.One place that young male voters found a sense of community and culture, Democrats say, is in the loose collection of podcasts often dubbed the “manosphere.”These podcasts — hosted by comedians such as Joe Rogan, Theo Von, Tim Dillon and Andrew Schulz — often make “you feel like you’re not alone,” Litman said.“It’s funny, often very funny. It’s a little subversive or often very subversive. It feels intimate. You get to know the hosts over the course of hours and hours of conversation: their lives and their, their personalities and their quirks, and I think that is really special. Like, the parasocial relationship can be very powerful,” she added.Litman’s conclusions about the power of these podcasts are backed up by a Priorities USA research project called Warbler, which works to understand voters’ online habits and media consumption.“One of the things I think that we were struck by in the research that we did is, people are looking for long-form , by and large,” said Jeff Horwitt from Hart Research, a Democratic polling firm that partnered with Priorities USA on some of the research. (Horwitt and his firm also partner with a Republican polling outfit on the NBC News poll.) “They want a conversational back and forth. They want to learn something new rather than be told something old.”Butterfield added that media consumption behavior among young voters is “fundamentally different” than even a decade ago.“We were teaching our candidates to, like, ‘Get in and get out,’ ‘Say what you need to say, and let that voter move on,’ because their attention spans are like goldfish,” she said.Now, Butterfield added, “that’s actually not the case. If you can get their attention, you’ll have their attention, right? It’s not about a lack of, a lack of eyeballs.”A Priorities poll of 5,000 voters conducted in September found that while a majority — 66% — of voters who reported listening to or watching certain “manosphere” podcasts in the past month voted for Trump in 2024, there was still a bright spot for Democrats in the research: an emerging break with Trump among this cohort.Of those “manosphere” Trump voters, 8% said they now disapproved of his performance as president, while 7% said they would vote for a Democrat on a generic congressional ballot.Meanwhile, some “manosphere” podcasters have broken with Trump on issues such as deportations, Israel’s war in Gaza and the Jeffrey Epstein files in recent months.Still, Butterfield warned, Democrats can’t take these cracks in Trump’s coalition as an automatic sign of support for Democrats.“We’re not going to just earn back all of these voters right away just because of their opposition to Trump. We’re going to have to make sure we are offering an alternative point of view, alternative policies that solve their economic anxieties, visions for the future, etc.,” she said.“That’s going to be the difference between an okay midterm and a really amazing midterm,” Butterfield continued, adding: “We’re not going to just get by on people hating Trump alone. We’ll get far-ish, but not as far as we need to go.”In last week’s New Jersey and Virginia elections, for example, Democratic Govs.-elect Mikie Sherrill and Abigail Spanberger won by larger-than-expected margins and made gains among young men in both states, exit polls show. But those margins among young men were still in line with their overall margins of victory, among an age group in which Democrats for years ran up the score compared to the overall electorate.‘Message, messenger and medium’ are the keysIn some ways, Democratic strategists and candidates say, the solution to their party’s concerns about its performance among young men — or at least the start of it — is as easy as just appearing on these podcasts and in other male-friendly spaces.It’s something several potential 2028 presidential candidates have already dabbled in. In April, former Transportation Secretary Pete Buttigieg sat for a nearly three-hour-long interview with the hosts of “Flagrant.” In July, California Gov. Gavin Newsom, a Democrat, participated in a four-hour-long podcast taping of the “Shawn Ryan Show.” Both these podcasts hosted Trump in 2024.The problem with this strategy, Litman pointed out, is that not all Democratic leaders are comfortable with appearing on such programs.“You shouldn’t force it, but for the leaders who are capable of having those kinds of conversations, I think they should absolutely go into those environments and be a little bit risk averse or a little bit risk tolerant, rather,” she said.“It’s both message, messenger and medium — it’s all of the above,” Litman added later.One 2025 election winner who embraced this strategy was New York City Mayor-elect Zohran Mamdani, who gained popularity on TikTok, appeared on popular social media shows like “Subway Takes,” and joined the “manosphere” podcast “Flagrant.”Allred cited these “manosphere” podcasts as one place more Democrats should be going, but said there are local spaces with the same informal, intimate environment — like high school football games — that many of his fellow Democrats should feel comfortable in but don’t.“I think that in the Democratic Party, there’s almost been a reluctance to engage in things like football, and I don’t really get that. I don’t think you have to be the biggest fan of it to know that this is a place where the community is gathering and people are having, at least for me, these are some of the realest conversations I have in the entire week,” he said.Appearing in these spaces would go a long way “in terms of people seeing us, not as, kind of, elite ivory tower policy wonks,” Allred added. “At a football game, you can have the same conversation about policy. It might be a little bit less wonkish, but it’ll be more authentic … I think it’s what most people are looking for in their leaders.”Looking ahead to 2026 and 2028, Butterfield said that a priority “is making sure that we’re not sticking out like sore thumbs in these kind of ‘entertainment-first’ spaces.”“I think that your ability to authentically communicate in these spaces should be a requirement to be a good candidate in today’s world, right?” she added. “We need to be holding our candidates to a high standard of electability, such that if you can’t come across as yourself on social media, maybe we need to pick a different candidate.”Alexandra MarquezAlexandra Marquez is a politics reporter for NBC News.
Related Post
October 1, 2025
Oct. 1, 2025, 5:00 AM EDTBy Abigail Brooks and Zinhle EssamuahWESTWEGO, Louisiana — Robin Phillip’s fresh haircut is dyed her favorite color — green. But beneath the dye job is a scar that runs along the side of her head, the result of two craniotomies. For years, Phillip, 45, suffered from what she thought were migraines. It wasn’t until early 2018, when she had to leave her warehouse shift to drive to the hospital, that she learned her headaches were a symptom of something more serious. She said she nearly crashed on the drive to the emergency room, blinded by pain. “The nurse said, ‘OK, what’s your pain from 1 to 10?’ I said 11, 12,” said Phillip. “They put me in the chair, and I don’t remember nothing after that.”Phillip awoke later to shocking news: She had an intracranial meningioma — a tumor of the lining of the brain. She needed emergency surgery.After the procedure, Phillip lost vision in her left eye and had to re-learn how to walk. Unable to work, she lost her apartment and moved in with her mother until she could get back on her feet. Robin Phillip during a radiation session in 2024. A mask holds her head in place for the treatment.Courtesy Robin Phillip“I was feeling lost, because where would I have possibly gotten a tumor from? I had a regular life. I did regular things,” she said. “What could have possibly caused this to happen to me?”Today, Phillip believes her birth control is to blame. For nearly 30 years, stopping only when she had her two children, she used Depo-Provera — a progestin shot given three times a year. She’s one of more than 1,000 women suing Pfizer, which makes the drug, alleging the company knew more about the risks and failed to warn users. Pfizer has moved to have the suit dismissed, arguing the case is pre-empted by a Food and Drug Administration decision, and says it stands behind the safety and efficacy of Depo-Provera.According to the Centers for Disease Control and Prevention, 1 in 4 sexually active women in the United States have used Depo-Provera. Black women use it at nearly double the national rate. Meningiomas are usually not cancerous — meaning they don’t spread to other parts of the body — but they can be harmful depending on their size and where they grow. Phillip’s tumor was pressing on her optic nerve, causing vision problems.Recent researchIn recent years, several studies have shown a possible link between Depo-Provera use and an increased risk of developing meningioma. One of them, published earlier this month in JAMA Neurology, linked medroxyprogesterone acetate (MPA), the drug in Depo-Provera, with a twofold increase in risk for meningioma. The risk was greatest in women who used the contraceptive for more than four years or started after age 31.Another one, a 2024 study published in the The BMJ based on French data, found a fivefold increase in risk for meningioma for long-term Depo-Provera users. Doctors caution that the studies are observational, meaning they cannot prove the medication caused the tumors. Dr. David Raleigh, a radiation oncologist who specializes in brain tumors and who is the chair of meningioma research at the University of California San Francisco’s Department of Radiation Oncology, said that female sex hormones — progesterone in particular — are linked to meningioma. (Progestin, the hormone in Depo-Provera, is a synthetic version of progesterone.) Meningiomas are the only brain tumors that are more common in women than in men, he added.Still, Raleigh said this doesn’t necessarily mean that progesterone is causing a meningioma to form. “All the available data suggest that progesterone is fuel on the fire,” he said. “Progesterone didn’t necessarily start the fire, but the available data suggest that it’s like dumping gas on it.” He said that the recent studies linking Depo-Provera to meningioma give him pause.“Those of us in the business often recommend that patients with meningioma avoid hormone replacement therapy, use nonhormone based means of contraception, if possible, and to be cautious with pregnancy and fertility planning because of these very well documented associations,” he said. “These new studies only amplify those concerns and considerations.”The overall risk of developing meningioma remains small: About 39,000 meningiomas are diagnosed each year in the U.S.“Overall, meningioma is not common. This is not a type of tumor that we see very often,” said Dr. Colleen Denny, an OB-GYN at NYU Langone Health. “The likelihood of having a meningioma as a Depo user is incredibly low. It’s just that it’s incredibly, incredibly low for people who don’t use Depo.”The American College of Obstetricians and Gynecologists (ACOG) published a response to The BMJ study urging caution, saying that, “according to the study, five out of 10,000 women using medroxyprogesterone acetate may possibly develop meningioma compared to one out of 10,000 women not using the medication.”“The risk that they’re finding is incredibly small,” said Dr. Nisha Verma, senior adviser for reproductive health policy for advocacy at ACOG. “I think it is a consideration we can talk to patients about, among all of the considerations that patients go through.”“Uterine cancer is a lot more common than meningioma, and Depo reduces your risk of uterine cancer. So how do you balance that?” Denny said. “It’s complex, and it often depends on the individual patients.”Phillip says even that small risk would have been too much for her.“If I would have [known] from the get-go, I would have never took that shot,” she said. The lawsuitPhillip is now one of more than 1,000 women suing Pfizer, the maker of Depo-Provera, alleging that the company failed to warn them about the risk. “These women all have meningiomas. Many have surgery, some have radiation, and they’ve all had their lives greatly impacted,” said Ellen Relkin, a lawyer representing Phillip and some of the other plaintiffs. Phillip’s lawsuit points to several studies dating as far back as 1983 showing a link between progesterone and meningioma. The lawsuit says those studies created an “unassignable duty to investigate,” and that Pfizer should have studied the risks associated with Depo-Provera sooner. Phillip needed two surgeries to remove a meningioma. A scar from the operations runs down the side of her head.NBC News“Defendants willfully, wantonly, and intentionally conspired, and acted in concert, to ignore relevant safety concerns and to deliberately not study the long-term safety and efficacy of Depo-Provera, particularly in chronic long-term users of Depo-Provera,” the complaint says. Verma, of ACOG, said that hormonal birth control is well-studied before it hits the market.“Birth control methods that are commercially available have been studied extensively before becoming available to the public, and so we’ve studied every type of birth control. We’ve looked at safety measures,” she said. “We have guidelines that do intensive reviews of all of the data and help us support patients in what methods may be safer for them.”In a statement to NBC News, Pfizer said it stands behind the “safety and efficacy of Depo-Provera.” In a court filing earlier this month, the company asked a judge to dismiss the case, saying that it became aware of the risks of meningioma associated with Depo-Provera in 2023, and submitted an application to the Food and Drug Administration to add a warning to the drug’s label. The application also requested adding warnings to two pills containing much lower doses of MPA. The FDA denied that request, according to the filing.The FDA declined NBC News’ request for comment, but in its denial letter to Pfizer, which is included in company’s filing, it said: “The findings of the available observational studies alone do not support the addition of a warning on Meningioma risk to medroxyprogesterone acetate (MPA)-containing products.”A spokesperson for Pfizer told NBC News that because of the FDA’s denial, federal law pre-empts the company from changing the warning label on Depo-Provera.In an interview with NBC News, Phillips’ lawyer Relkin said Pfizer had enough information to study the possible risks associated with Depo-Provera on its own before 2023 and accused the company of making an “overbroad and half-baked” effort to warn patients by submitting an application to add a warning label to every medication containing MPA.“Depo-Provera is 150 milligrams. Three, four times a year, a very high dose,” Relkin said. “There are low-dose, 2.5 and 5 mg pills, where there’s no data showing that they cause a problem.”“The dose makes the poison,” she added. “By asking to change the label for all, they were inviting a rejection.”Pfizer denied that accusation in its court filing. “If FDA truly thought a meningioma warning was necessary for some products (and not others) … FDA could have ‘promptly’ communicated to Pfizer,” it wrote.Changes abroad Outside of the U.S., however, changes have been made to Pfizer’s label.The European Medicines Agency added meningioma as a “possible side effect” of drugs with high doses of medroxyprogesterone acetate in 2024, and Pfizer went on to communicate that risk to doctors in the European Union. Canada’s label for the drug, updated in 2024, includes meningioma in its “warnings and precautions” section, stating that “meningiomas have been reported following long-term administration of progestins, including medroxyprogesterone acetate.”In January, South Africa’s drug regulatory agency also recommended updating the drug label for MPA to include meningioma risk. Phillip’s lawsuit alleges that Pfizer knew of the potential risk years before those changes overseas were made, however, citing a 2006 Canadian drug label which lists meningioma as one of the “Post-Market Adverse Drug Reactions” — adverse events that are reported after a drug has already been approved. The 2006 label notes that “the nature of post-marketing surveillance makes it difficult to determine if a reported event was actually caused by DEPO-PROVERA.”“Just because something happened associated in time with something, it doesn’t mean that one thing caused the other,” said Dr. Janet Woodcock, a former FDA principal deputy commissioner. “It’s in a company’s best interest to put everything on there, because then if they’re sued, they’d say, ‘Well, it was in the fine print.’”Woodcock, who is not involved with the lawsuit, noted the FDA typically has the final word on drug labels.According to Pfizer’s court filings, the company resubmitted its application to the FDA in June 2025. Phillip, right, rings the bell on her last day of radiation treatment on March 25, 2024.Courtesy Robin Phillip“FDA has still not approved any meningioma warning, and Pfizer’s renewed request remains pending,” the filing said.Relkin said an earlier warning would have changed everything for Phillip and her other clients.After her surgery in 2018, Phillip continued to take Depo-Provera. Her doctors were unable to remove the entire tumor in 2018 and she needed a second surgery in 2022, followed by radiation treatment from 2022 to 2024.Even still, doctors weren’t able to remove the entire tumor because of how close it is to her optic nerve.Phillip says she continued taking Depo-Provera until she saw posts on social media in 2024 about the studies linking the drug to meningioma. Earlier this month, she had her first set of brain scans since going off the drug. She said her radiologist told her that the meningioma is shrinking. “My body is telling me, my head is telling me I don’t have that much pain like I used to have,” she said. Abigail BrooksAbigail Brooks is a producer for NBC News.Zinhle EssamuahZinhle Essamuah is a correspondent and anchor for NBC News.
September 30, 2025
Schumer reacts to Trump's AI-generated post about him
October 13, 2025
Seven hostages handed over from Hamas to the Red Cross
October 11, 2025
Savewith a NBCUniversal ProfileCreate your free profile or log in to save this articleOct. 11, 2025, 5:15 AM EDTBy Jeremy Mikula and Melinda YaoLeBron James pulls a fast one, the Nobel Peace Prize gets awarded, and a musical beef gets adjudicated. Test your knowledge of this week’s news, and take last week’s quiz here. Jeremy MikulaJeremy Mikula is the weekend director of platforms for NBC News.Melinda YaoI am an intern for data graphics team.Kyna Doles, Richie Duchon, Josh Feldman, Lara Horwitz and Amina Kilpatrick contributed.
Comments are closed.
Scroll To Top
  • Home
  • Travel
  • Culture
  • Lifestyle
  • Sport
  • Contact Us
  • Politics
© Copyright 2025 - Be That ! . All Rights Reserved